Biohaven licenses epilepsy drug to SK Biopharmaceuticals for up to $795 million

• The deal is worth up to $795 million, representing a significant licensing transaction in the epilepsy treatment space
• The agreement covers Biohaven's epilepsy drug platform with Opakalim as a key asset included in the licensing arrangement
• SK Biopharmaceuticals, a South Korean pharmaceutical company, gains rights to develop and market these epilepsy therapies

Summary

Key Transaction Details:

Biohaven has entered into a licensing agreement with South Korean pharmaceutical company SK Biopharmaceuticals for Biohaven's epilepsy drug platform, with a total deal value of up to $795 million. The agreement, announced Wednesday, August 26, centers on Biohaven's epilepsy drug candidate Opakalim and related platform assets.

Companies Involved:

• Biohaven (licensor): U.S.-based biopharmaceutical company
• SK Biopharmaceuticals (licensee): South Korean drug manufacturer

Market Implications:

This licensing deal represents a significant validation of Biohaven's epilepsy drug platform and provides substantial potential revenue through milestone payments. For SK Biopharmaceuticals, the agreement expands its neurology portfolio and provides access to promising epilepsy treatments, a therapeutic area with significant unmet medical needs globally.

The $795 million figure likely includes upfront payments plus development, regulatory, and commercial milestone payments, though specific payment structure details were not disclosed in the announcement.

Sector Context:

This transaction highlights continued investor and pharmaceutical industry interest in neurology treatments, particularly for epilepsy, which affects millions worldwide. Cross-border licensing deals between U.S. and Asian pharmaceutical companies remain a common strategy for expanding market reach and sharing development costs and risks.

The deal provides Biohaven with non-dilutive funding to support its broader pipeline while allowing SK Biopharmaceuticals to strengthen its position in the competitive epilepsy treatment market.